Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 27.86
DXCM's Cash to Debt is ranked higher than
62% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. DXCM: 27.86 )
Ranked among companies with meaningful Cash to Debt only.
DXCM' s 10-Year Cash to Debt Range
Min: 0.4  Med: 16.21 Max: No Debt
Current: 27.86
Equity to Asset 0.78
DXCM's Equity to Asset is ranked higher than
75% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. DXCM: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
DXCM' s 10-Year Equity to Asset Range
Min: -0.63  Med: 0.72 Max: 0.92
Current: 0.78
-0.63
0.92
F-Score: 7
Z-Score: 89.23
M-Score: -3.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -6.17
DXCM's Operating margin (%) is ranked lower than
55% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. DXCM: -6.17 )
Ranked among companies with meaningful Operating margin (%) only.
DXCM' s 10-Year Operating margin (%) Range
Min: -2272.81  Med: -93.13 Max: -8.29
Current: -6.17
-2272.81
-8.29
Net-margin (%) -6.42
DXCM's Net-margin (%) is ranked lower than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. DXCM: -6.42 )
Ranked among companies with meaningful Net-margin (%) only.
DXCM' s 10-Year Net-margin (%) Range
Min: -2147.42  Med: -113.45 Max: -8.64
Current: -6.42
-2147.42
-8.64
ROE (%) -15.21
DXCM's ROE (%) is ranked lower than
58% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. DXCM: -15.21 )
Ranked among companies with meaningful ROE (%) only.
DXCM' s 10-Year ROE (%) Range
Min: -60568.63  Med: -73.89 Max: -19.97
Current: -15.21
-60568.63
-19.97
ROA (%) -11.50
DXCM's ROA (%) is ranked lower than
58% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. DXCM: -11.50 )
Ranked among companies with meaningful ROA (%) only.
DXCM' s 10-Year ROA (%) Range
Min: -178.43  Med: -68.09 Max: -14.59
Current: -11.5
-178.43
-14.59
ROC (Joel Greenblatt) (%) -37.10
DXCM's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. DXCM: -37.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DXCM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3333.88  Med: -731.48 Max: -50.89
Current: -37.1
-3333.88
-50.89
Revenue Growth (3Y)(%) 43.80
DXCM's Revenue Growth (3Y)(%) is ranked higher than
96% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. DXCM: 43.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DXCM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 14.65 Max: 103.1
Current: 43.8
0
103.1
EBITDA Growth (3Y)(%) -35.00
DXCM's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. DXCM: -35.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DXCM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -28.05 Max: 0.6
Current: -35
0
0.6
EPS Growth (3Y)(%) -23.90
DXCM's EPS Growth (3Y)(%) is ranked lower than
75% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. DXCM: -23.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DXCM' s 10-Year EPS Growth (3Y)(%) Range
Min: -40.1  Med: -19.80 Max: 37.1
Current: -23.9
-40.1
37.1
» DXCM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

DXCM Guru Trades in Q3 2014

Joel Greenblatt Sold Out
Ron Baron 1,345,322 sh (-0.24%)
Mario Gabelli 66,000 sh (-6.38%)
RS Investment Management 433,460 sh (-19.53%)
» More
Q4 2014

DXCM Guru Trades in Q4 2014

Joel Greenblatt 9,915 sh (New)
Jim Simons 269,343 sh (New)
RS Investment Management 535,254 sh (+23.48%)
Ron Baron 1,340,731 sh (-0.34%)
Mario Gabelli 51,600 sh (-21.82%)
» More
Q1 2015

DXCM Guru Trades in Q1 2015

Joel Greenblatt Sold Out
Ron Baron 1,338,407 sh (-0.17%)
Mario Gabelli 50,800 sh (-1.55%)
RS Investment Management 354,260 sh (-33.81%)
Jim Simons 69,343 sh (-74.25%)
» More
Q2 2015

DXCM Guru Trades in Q2 2015

RS Investment Management 573,480 sh (+61.88%)
RS Investment Management 573,480 sh (+61.88%)
Mario Gabelli 50,800 sh (unchged)
Ron Baron 1,337,607 sh (-0.06%)
Jim Simons 26,900 sh (-61.21%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on DexCom Inc

Baron Funds Comments on DexCom Inc. - Aug 19, 2015

DexCom, Inc. (NASDAQ:DXCM) sells a continuous glucose monitoring device for insulin dependent diabetes. DexCom reported very strong results. Revenues grew 55% in the quarter, and the company reiterated guidance for continued exceptional growth. The company launched its “share” system, which allows parents or spouses to receive the users’ blood glucose data from the users’ handheld devices, an important new feature. And they filed for approval of their next generation offering that will transmit data directly to a smartphone, eliminating the need to carry a receiver. Strong new patient starts, more accurate and feature rich products, and an expanding addressable market make for a company that, we believe, can grow rapidly for a considerable time go forward.



From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about DexCom Inc

Baron Funds Comments on DexCom Inc.
DexCom, Inc. (NASDAQ:DXCM) sells a continuous glucose monitoring device for insulin dependent diabetes. DexCom reported very strong results. Revenues grew 55% in the quarter, and the company reiterated guidance for continued exceptional growth. The company launched its “share” system, which allows parents or spouses to receive the users’ blood glucose data from the users’ handheld devices, an important new feature. And they filed for approval of their next generation offering that will transmit data directly to a smartphone, eliminating the need to carry a receiver. Strong new patient starts, more accurate and feature rich products, and an expanding addressable market make for a company that, we believe, can grow rapidly for a considerable time go forward. Read more...

Ratios

vs
industry
vs
history
Forward P/E 303.03
DXCM's Forward P/E is ranked lower than
98% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.12 vs. DXCM: 303.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 44.18
DXCM's P/B is ranked lower than
99% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. DXCM: 44.18 )
Ranked among companies with meaningful P/B only.
DXCM' s 10-Year P/B Range
Min: 3.88  Med: 14.93 Max: 209.25
Current: 44.18
3.88
209.25
P/S 22.85
DXCM's P/S is ranked lower than
88% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. DXCM: 22.85 )
Ranked among companies with meaningful P/S only.
DXCM' s 10-Year P/S Range
Min: 6.36  Med: 15.06 Max: 1058.5
Current: 22.85
6.36
1058.5
PFCF 428.01
DXCM's PFCF is ranked lower than
99% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.28 vs. DXCM: 428.01 )
Ranked among companies with meaningful PFCF only.
DXCM' s 10-Year PFCF Range
Min: 329.27  Med: 580.86 Max: 753.29
Current: 428.01
329.27
753.29
POCF 184.56
DXCM's POCF is ranked lower than
99% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. DXCM: 184.56 )
Ranked among companies with meaningful POCF only.
DXCM' s 10-Year POCF Range
Min: 142.04  Med: 195.91 Max: 1503.33
Current: 184.56
142.04
1503.33
Current Ratio 3.86
DXCM's Current Ratio is ranked higher than
64% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. DXCM: 3.86 )
Ranked among companies with meaningful Current Ratio only.
DXCM' s 10-Year Current Ratio Range
Min: 1.96  Med: 4.42 Max: 23.47
Current: 3.86
1.96
23.47
Quick Ratio 3.35
DXCM's Quick Ratio is ranked higher than
66% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. DXCM: 3.35 )
Ranked among companies with meaningful Quick Ratio only.
DXCM' s 10-Year Quick Ratio Range
Min: 1.82  Med: 4.04 Max: 23.47
Current: 3.35
1.82
23.47
Days Inventory 60.25
DXCM's Days Inventory is ranked higher than
57% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. DXCM: 60.25 )
Ranked among companies with meaningful Days Inventory only.
DXCM' s 10-Year Days Inventory Range
Min: 23.53  Med: 49.97 Max: 73.69
Current: 60.25
23.53
73.69
Days Sales Outstanding 52.01
DXCM's Days Sales Outstanding is ranked higher than
67% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. DXCM: 52.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXCM' s 10-Year Days Sales Outstanding Range
Min: 16.96  Med: 50.07 Max: 71.25
Current: 52.01
16.96
71.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 151.92
DXCM's Price/Net Cash is ranked lower than
100% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. DXCM: 151.92 )
Ranked among companies with meaningful Price/Net Cash only.
DXCM' s 10-Year Price/Net Cash Range
Min: 4.94  Med: 30.17 Max: 166
Current: 151.92
4.94
166
Price/Net Current Asset Value 61.56
DXCM's Price/Net Current Asset Value is ranked lower than
91% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.45 vs. DXCM: 61.56 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DXCM' s 10-Year Price/Net Current Asset Value Range
Min: 4.88  Med: 19.41 Max: 53.03
Current: 61.56
4.88
53.03
Price/Tangible Book 45.72
DXCM's Price/Tangible Book is ranked lower than
97% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. DXCM: 45.72 )
Ranked among companies with meaningful Price/Tangible Book only.
DXCM' s 10-Year Price/Tangible Book Range
Min: 4.7  Med: 13.93 Max: 154.75
Current: 45.72
4.7
154.75
Price/Median PS Value 1.52
DXCM's Price/Median PS Value is ranked lower than
79% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. DXCM: 1.52 )
Ranked among companies with meaningful Price/Median PS Value only.
DXCM' s 10-Year Price/Median PS Value Range
Min: 0.53  Med: 0.99 Max: 45.27
Current: 1.52
0.53
45.27
Earnings Yield (Greenblatt) (%) -0.29
DXCM's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. DXCM: -0.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DXCM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.6  Med: 0.00 Max: 0
Current: -0.29
-0.6
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 379 532 706
EPS($) -0.14 0.31 0.79
EPS without NRI($) -0.14 0.31 0.79

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:DC4.Germany,
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company's SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
Panic-Proofing the Small Investor Aug 26 2015 
Baron Funds Comments on DexCom Inc. Aug 19 2015 
Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc. Jul 20 2015 
Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM Jul 14 2015 
Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc. Jul 13 2015 
Dexcom’s Smart Glucose Monitoring System Receives FDA Approval Jan 27 2015 
Top Insider Sells Highlight: Dexcom Inc. Aug 22 2014 
DexCom Reports $1 Million Insider Buy Mar 12 2013 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2010 
DexCom Inc. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
DexCom Wins FDA Approval for G5 CGM System; Stock Up Aug 26 2015
FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System Aug 25 2015
FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System Aug 25 2015
FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System Aug 25 2015
Is this CEO going to take on Trump? Aug 14 2015
Jim Cramer's Top Takeaways: Take-Two Interactive, DexCom, Martin Marietta Aug 14 2015
Jim Cramer's 'Mad Money' Recap: Cult Stocks Amazon, Netflix Gave Bulls a Boost Aug 13 2015
Cramer Remix: China is totally crushing this stock Aug 13 2015
Cramer: A new generation of diabetes healthcare Aug 13 2015
DEXCOM INC Financials Aug 13 2015
Monitor your blood sugar, courtesy of Google Aug 13 2015
DexCom Shares Gain on Google Deal: Should You Consider? Aug 12 2015
Major support under siege after China’s currency move Aug 11 2015
DexCom Inc Conference Call to Discuss Collaboration with the Life Sciences Team at Google on the... Aug 11 2015
DexCom to Collaborate with the Life Sciences Team at Google on the Development of Breakthrough... Aug 11 2015
DEXCOM INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Aug 11 2015
DexCom to Collaborate with the Life Sciences Team at Google on the Development of Breakthrough... Aug 11 2015
DexCom To Collaborate With The Life Sciences Team At Google On The Development Of Breakthrough... Aug 11 2015
10-Q for DexCom, Inc. Aug 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK